![logo](/logos/ORIC.webp)
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
9.65 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | ORIC Pharmaceuticals, Inc. |
Symbool | ORIC |
Munteenheid | USD |
Prijs | 9.65 |
Beurswaarde | 680,735,125 |
Dividendpercentage | 0% |
52-weken bereik | 5.27 - 16.65 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jacob M. Chacko M.B.A., M.D. |
Website | https://www.oricpharma.com |
An error occurred while fetching data.
Over ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)